Zy Therapeutics
Zy Therapeutics is a biomedical company focused on developing disease-modifying therapies that target brain calcifications in rare central nervous system (CNS) disorders. The company is developing a reformulated small-molecule therapy optimized for brain delivery and improved bioavailability, with an emphasis on rare/orphan and pediatric populations and on partnering for clinical development and commercialization.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
US-10994024-B2
View Details
Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
US-10994024-B2
View DetailsProducts
Kamini (ZY-001)
A reformulated version of disodium etidronate optimized for brain delivery and improved bioavailability, developed as a disease-modifying therapy to target brain calcifications associated with rare CNS disorders.
Kamini (ZY-001)
A reformulated version of disodium etidronate optimized for brain delivery and improved bioavailability, developed as a disease-modifying therapy to target brain calcifications associated with rare CNS disorders.
Services
Strategic collaborations and co-development partnerships to advance reformulated CNS therapies toward clinical development and commercialization.
Strategic collaborations and co-development partnerships to advance reformulated CNS therapies toward clinical development and commercialization.
Expertise Areas
- Rare disease drug development
- CNS-targeted drug delivery
- Drug reformulation and repurposing
- Clinical program design and execution
Key Technologies
- Small-molecule reformulation
- Brain/CNS delivery optimization
- Bioavailability enhancement
- Drug repurposing strategies
News & Updates
Company representatives attended the BIO International Convention to meet potential partners and collaborators in Boston, MA.
Company representatives attended the BIO International Convention to meet potential partners and collaborators in Boston, MA.